Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate Safety, Immunogenicity of the ChulaCov19 BNA159 mRNA Vaccine in Healthy Adults

NCT05231369 is registered in ClinicalTrials.gov with Chulalongkorn University as lead sponsor.

NCT NCT05231369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05231369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate Safety, Immunogenicity of the ChulaCov19 BNA159 mRNA Vaccine in Healthy Adults
Lead sponsor
Chulalongkorn University
Phase
Phase 1
Overall status
Unknown status
Start date
December 14, 2022
Completion date
July 1, 2023
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

assess which dose is appropriate to use, immune response of 25 ug of chulacov19-bna159 mrna vaccine, immune response of 50 ug of chulacov19-bna159 mrna vaccine, safety of 25 ug of chulacov19-bna159 mrna vaccine, safety of 50 ug of chulacov19-bna159 mrna vaccine, tolerability of 25 ug of chulacov19-bna159 mrna vaccine, tolerability of 50 ug of chulacov19-bna159 mrna vaccine